Table 3.
Administration route | Advantages32 | Disadvantages32 | Examples | Time to peak plasma concentration |
---|---|---|---|---|
Intramuscular | Rapid systemic entry; patient cooperation not necessary | Invasive; can damage patient–physician relationship | Haloperidol24 | ~20 minutes |
Olanzapine27 | 15–45 minutes | |||
Aripiprazole28 | 1–3 hours | |||
Ziprasidone26 | 60 minutes | |||
Inhaled | Less invasive than intramuscular route and can improve patient experience. Enters alveoli for rapid entry into arterial circulation | Requires patient cooperation Bronchospasm/respiratory distress |
Loxapine31 | 2 minutes |
Oral | ||||
Standard tablets/capsules/solution | Less invasive than intramuscular route and can improve patient experience | Require patient cooperation; slow onset of action; enter systemic circulation via portal system resulting in potential for erratic absorption; can be diverted (“cheeking”) | Haloperidol24 | 2–6 hours |
Olanzapine27 | 5–8 hours | |||
Risperidone30 | ~1 hour | |||
Aripiprazole28 | 3–5 hours | |||
Ziprasidone26 | 6–8 hours | |||
Orally disintegrating tablets | Less invasive than intramuscular route and can improve patient experience. Less potential for diversion (“cheeking”) vs standard tablets/capsules; suitable for patients with dysphagia | Slow onset of action; enter systemic circulation via portal system resulting in potential for erratic absorption | Olanzapine27 | ~6 hours |
Risperidone30,33,34 | 1–2 hours | |||
Aripiprazole28 | 3–5 hours | |||
Buccal/sublingual | Less invasive than intramuscular route and can improve patient experience; rapid absorption; avoids first-pass metabolism | Requires patient cooperation; needs to be taken correctly so that it is not swallowed, mitigated in part by the friability of the tablet | Sublingual asenapine35 | 0.5–1.5 hours |
Intranasal | Less invasive than intramuscular route and can improve patient experience; rapid absorption; avoids first-pass metabolism | Requires patient cooperation. | Intranasal midazolam32 | 10 minutes |